Duchenne News Tags: Dyne

November 7, 2022
Dyne Therapeutics receives FDA Fast Track designation for DYNE-251 for treatment of Duchenne
August 11, 2022
On August 10, 2022, Dyne Therapeutics announced the publication of Duchenne muscular dystrophy preclinical data: Enhanced Exon Skipping and Prolonged Dystrophin Restoration Achieved by TfR1-Targeted Delivery of Antisense Oligonucleotide Using FORCE Conjugation in Mdx Mice.
July 5, 2022
On July 5, 2022, Dyne Therapeutics announced that the U.S. Food and Drug Administration lifted the hold and cleared their Investigational New Drug application for DYNE-251.